LLOYD-SMITH D L, MCNAUGHTON F L
Can Med Assoc J. 1963 Dec 14;89(24):1221-3.
Methysergide was used as a regular medication to prevent migraine in a series of 87 patients with frequently recurring severe attacks of three types, common, classical and cluster migraine, in a study conducted during a 30-month period. Results were classified as excellent, good, fair and nil. The total reporting excellent and good results was 50.6%. In a few patients the drug appeared to lose effectiveness in long-term treatment. Other investigators have described more favourable results, notably Friedman, who reported improvement in common migraine in 79% of patients and in cluster migraine in 90% of patients. Side effects were noted in 34.2% of patients and led to discontinuing the trial in 10.4%; these promptly subsided when the drug was withdrawn. Methysergide appears to be a useful additional agent for prevention of severe, frequently recurring migraine of common and cluster type. In this small series it had little effect on headaches of combined tension and vascular type.
在一项为期30个月的研究中，对87例经常反复发作三种类型（普通型、典型型和丛集性偏头痛）严重偏头痛的患者，使用麦角新碱作为预防偏头痛的常规药物。结果分为优、良、中、差。报告优和良结果的总数为50.6%。在少数患者中，该药物在长期治疗中似乎失去了疗效。其他研究者描述了更有利的结果，特别是弗里德曼，他报告普通型偏头痛患者中有79%得到改善，丛集性偏头痛患者中有90%得到改善。34.2%的患者出现了副作用，导致10.4%的患者中断试验；停药后这些副作用迅速消退。麦角新碱似乎是预防普通型和丛集性严重、频繁复发偏头痛的一种有用的辅助药物。在这个小系列研究中，它对合并紧张型和血管型头痛几乎没有效果。
